Exploring Brain-Computer Interface Technology

Brain Damage - Causes & Symptoms Of It!

There are two types of brain damage, both of which interfere with the standard functioning of the brain.

They are:Acquired brain injury (ABI): Either resulting from a tumor or a neurological illness, for instance a stroke, this type of brain injury originates from the cellular level and is commonly linked with brain pressure.
Traumatic brain injury (TBI): It results from any damage imparted to the skull usually from an external and physical force like a blow to the head or a head accident, which in turn damages the brain.

How severe the brain damage is depends largely on the type of brain injury. Mild brain injuries are temporary, causing headaches, memory lapses, nausea and confusion. On the other hand, severe brain injuries cause cognitive, physical and behavioral impairments which are often life-changing and permanent.

Causes:

Acquired brain injuries may be caused by:

Poisoning

• Being exposed to toxic substances
• Choking, strangulation or drowning
• Heart attacks
• Infections
• Stroke

1. Tumors

• Neurological illnesses
• Aneurysms
• Illegal drug abuse

Traumatic brain injuries are usually caused by:

• Car accidents
• Sports injuries
• Physical violence
• Head blows
• Falls and other mishaps

Symptoms:

Whether acquired or traumatic, symptoms of brain damage can be classified under four major groups:

1. Cognitive symptoms generally includeHaving a hard time processing information or expressing thoughts
Difficulty in understanding others or abstract concepts
Indecisiveness
Memory loss
Short attention spans

2. Physical symptoms generally includeExcessive physical fatigue
Extreme mental fatigue
Persistent and frequent migraines or headaches
Paralysis
Seizures
Tremors
Sleep disorders
Light sensitivity
Loss of consciousness
Slurred speech

3. Perceptual symptoms generally includeSpatial disorientation
Smell and taste disorders
Heightened pain sensitivity
Changes in hearing, seeing, or touch sensations
Unable to perceive time
Balance problems

4. Emotional or behavioral symptoms generally includeDecreased stress tolerance
Heightened or flattened reactions or emotions
Aggressiveness
Sluggishness
Impatience and irritability
Self-denial

Visit: neurology.pencis.com

#BrainDamage#NeurologicalInjury#CognitiveImpairment#TraumaticBrainInjury#StrokeRecovery#BrainHealing#BrainHealth#Neurorehabilitation#ConcussionAwareness#BrainInjurySupport#Neurology#BrainFunction#Neuroscience#BrainRecovery#BrainResearch#BrainPlasticity#Neuropsychology#BrainAwareness#BrainWellness#BrainInjuryAwareness

"NeuroQuest: Journey into CNS"

Negative Emotions More Prominent In Executives Who Take Fewer Risks

Executives who take the fewest risks have the most negative emotions

“We have analysed emotional traits of low intensity. In this context, the higher the negative emotional traits are, the fewer risks taken by the bodies managed by the directors”, Juan Bautista Delgado García, co-author of the study and researcher at UBU declares to SINC.

The study, which is published in the British Journal of Management, was produced based on a survey sent in 2004 to all the managing directors and general directors of Spanish banks and savings banks (70 banks and 46 savings banks). The survey had a response rate of 48.3% and contained a selection of questions related to the emotional traits and demographic characteristics of the executives.

In addition, to evaluate the level of economic risk of banks and savings banks, various measurements were used related to the general risk, the credit risk and lending portfolios (commercial credits, credits with guarantee in rem and financial leases), with the information obtained based on the annual accounts of the Banks.

The methodology that the scientists used attempted to condense the two main emotional traits, positive and negative ones, based on a commonly used scale, the PANAS scale of negative (such as nervousness or irritation) and positive (such as interest or enthusiasm) emotional traits.

“It is worth pointing out that although it may not seem so, these two types of emotional traits are two separate dimensions of the character of any individual. An individual can be very emotional, not emotional at all, or be very emotional in positive traits and not at all in negative ones and vice versa”, explains Delgado.

the credit risk, in three main types of credits: commercial credits, credits with guarantee in rem (with some type of guarantee in rem linked, like mortgages) and finally, financial leases (those in which the lessee is expected to substantially assume all the profits, costs and risks inherent to the property).

“What has been observed is that the greater the negative emotional traits of the directors, the higher the proportion of credits with guarantees in rem the bank has and the fewer financial leases. In the case of commercial credits, no form of influence on emotions was detected”, the expert points out.

More risks assumed at higher levels of studies

The investigation also compares the connection between business risk and previous experience in the banking sector, educational level, experience of the executive in a risk area and their participation in property.

“The most significant of these aspects is the educational level of the directors, in other words, it has an influence if the director has a degree, a master’s or a doctorate. The higher the degree, the greater the level of risk assumed by the bank they manage”, states Delgado.

visit: neurology.pencis.com

#neurons

#neuroscience

#brain

#neurology

#neurobiology

#synapses

#neuroplasticity

#cognitive

#neuroresearch

#neuroimaging

#neuroscientist

#brainhealth

#neurotransmitters

#neuropsychology

#neurodegenerative

#neurodevelopment

#brainfunction

#neurologicaldisorders

#neuromodulation

#neurotech

Visceral motor system.

Finding Light in the Darkness: A CNS Depression Blog

Central nervous system (CNS) depression happens when the body’s neurological functions slow down. It can result from substance overdoses, poisoning, or other medical conditions.

What is CNS depression?

A person may benefit from taking the correct dose of a CNS depressant, such as an opioid pain relief medication.

But, high doses of these drugs can reduce the activity of the CNS to dangerously low levels.

The CNS consists of the brain and spinal cord. It controls most bodily functions — including breathing and the heart — by sending messages between the brain and other nerves via the spinal cord.

Symptoms

People can have varying symptoms of CNS depression or depressant overdose. Factors that affect the impact of CNS depression include:the cause

• the type and dose of a substance
• the severity of the illness or injury
• the size of the individual
• the person’s medical history

Medications, drugs, and other substances

The main substances that cause CNS depression are:

• alcohol
• barbiturates
• benzodiazepines
• opioids

Most of these drugs cause some combination of drowsiness, muscle relaxation, and anxiety reduction.

These substances carry a risk of addiction. Combining them can lead to Trusted Source severe and potentially life-threatening adverse effects.

Combining substances

Mixing CNS depressants, opioids, and alcohol increases their effect. There may be severe adverse reactions and possibly life-threatening consequences.

Sometimes, a person may not realize they are at risk of an overdose, such as when they use opioid pain relief medication and then drink alcohol.

Treatment

Treatment for CNS depression or CNS depressant overdose depends on the substances involved.

Some CNS drugs have antidotes that can reverse their effects. These include Naloxone for opioid overdoses and Flumazenil for overdoses of benzodiazepine.

A person may need emergency care if they are unaware that they are experiencing a CNS depressant overdose, especially after accidentally misusing their medication or due to a medical problem.

Anyone witnessing signs of CNS depression or an overdose in another person should call the emergency services or local poison control center for guidance.

visit: neurology.pencis.com

#CNSDepression#DepressedNervousSystem#NeurologicalDepression#DepressedBrain#CNSDepressants#CentralNervousSystemDepression#BrainDepression#Neurodepression#CNSDepressionAwareness#MentalSluggishness#NeurologicalSlump#BrainSuppression#CNSDownturn#NeurologicalDullness#DepressedNeurochemistry#CNSFunctionImpairment#MentalInhibition#BrainDepressedState#CNSDepressionSupport#NeurologicalLethargy

"Neurological Disorders: Diagnosis and Management"

Global Neurology Devices Market Size To Worth $23.90 Billion By 2030

The Global Neurology Devices Market Size to grow from USD 14.1 billion in 2021 to USD 23.90 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 8.5% during the forecast period.

COVID 19 Impact

The COVID 19 pandemic is expected to have a significant impact on the world's healthcare systems, with severe consequences for not only those who are infected with COVID 19 but also for others. As a result, treatment and surgeries have had to be postponed in order to manage and reserve resources. For instance, in June 2020, the World Health Organisation (WHO) released the results of a survey that was carried out by 155 countries over the course of three weeks in May 2020. The survey focused on the prevention and treatment of various chronic diseases, including neurodegenerative disorders like dementia and Parkinson's disease, which have become a source of concern for patients with severe illnesses.

In an effort to lessen the severity and likelihood of patient death from neurovascular conditions, medical professionals and neurosurgeons have begun to investigate alternate therapeutic options. The need for neurovascular treatments is rising dramatically in several nations, including Japan, the United States, China, Germany, and India, since the number of patients with neurovascular disorders is rising and their medical conditions are becoming more severe.

Additionally, it is predicted that the market for neurological disorders would develop due to the rise in neurological illnesses, rising demand for minimally invasive procedures, and technical advancements in neurology equipment. Devices used in interventional neurology are frequently utilised to diagnose and treat vascular disorders of the brain and central nervous system.

Product Insights

Neurostimulation devices segment is dominating the market with the largest market share over the forecast period

On the basis of product, the global neurology devices market is segmented into neurostimulation, CSF management, interventional neurology, and neurosurgery devices. Among these, neurostimulation devices segment holds the largest market share over the forecast period. The ability of this device to treat nervous system and locomotor problems is credited with the rise. of addition to this, a second factor influencing segmental expansion is the increase of chronic nerve condition instances.

On the other hand, the category of interventional neurology is experiencing the quickest rate of market expansion due to the rise in shunting techniques and the prevalence of hydrocephalus, both of which are positively affecting market growth.

Regional Insights

North America is dominating the market with the largest market share over the forecast period

Due to the strategic government initiatives, high end healthcare infrastructure, and research and development in neuroscience, pharmaceuticals, and brain tumours, as well as the crucial presence of high CNS research, North America is dominating the market with the largest market share over the forecast period. These factors are driving regional growth.

On the other hand, Asia Pacific is experiencing the fastest market growth due to the region's high medical demand, significant increase in investments in the industry's research and development, and rising healthcare costs in developing nations like China and India.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the global Neurology Devices Market based on the below-mentioned segments:

visit:neurology.pencis.com.

#NeurologyDevices

#Neurotech

#Neuroscience

#NeurologicalDevices

#NeurologicalDisorders

#MedicalDevices

#NeurologyMarket

#NeurologicalTechnology

#BrainHealth

#NeuroImaging

#Neurotherapy

#Neurostimulation

#NeurologicalResearch

#NeurologicalSurgery

#Neurologists

#NeuroRehabilitation

#BrainMonitoring

#NeurologyInnovation

#NeurologicalCare

#neurologyconference

Working memory changes in post-COVID condition

AI-Assisted Diagnosis in Neurology Market 2023 | Futuristic Technology- BioMind, Arterys, Brain Scientific, Methinks, Neuro-AI

The AI-Assisted Diagnosis in Neurology research report combines vital data incorporating the competitive landscape, global, regional, and country-specific market size, market growth analysis, market share, recent developments, and market growth in segmentation. Furthermore, the AI-Assisted Diagnosis in Neurology research report offers information and thoughtful facts like share, revenue, historical data, and global market share. It also highlights vital aspects like opportunities, driving, product scope, market overview, and driving force.

our experts utilize industry techniques to collate and examine data at all stages. The report incorporates upstream crude materials and downstream necessities examinations. The most notable players in the market are analyzed. The AI-Assisted Diagnosis in Neurology research report provides an itemized outline of noticed market patterns and critical regions with development potential. The investigation gauges the development in market size, piece of the pie, request, practices, and gross deals of AI-Assisted Diagnosis in Neurology market.

The report provides a comprehensive analysis of company profiles listed below:

- BioMind

- Arterys

- Brain Scientific

- Methinks

- Neuro-AI

AI-Assisted Diagnosis in Neurology Market Segment by Type:

- Hardware

- Software

AI-Assisted Diagnosis in Neurology Market Segment by Application:

- Visualization Analysis

- Diagnoses

- Others

The study report offers a comprehensive analysis of AI-Assisted Diagnosis in Neurology Market size across the globe as regional and country level market size analysis, CAGR estimation of market growth during the forecast period, revenue, key drivers, competitive background and sales analysis of the payers. Along with that, the report explains the major challenges and risks to face in the forecast period. AI-Assisted Diagnosis in Neurology Market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global AI-Assisted Diagnosis in Neurology Market will be able to gain the upper hand as they use the report as a powerful resource.

Scope of this Report:

• This report segments the global AI-Assisted Diagnosis in Neurology market comprehensively and provides the closest approximations of the revenues for the overall market and the sub-segments across different verticals and regions.

• The report helps stakeholders understand the pulse of the AI-Assisted Diagnosis in Neurology market and provides them with information on key market drivers, restraints, challenges, and opportunities.

• This report will help stakeholders to understand competitors better and gain more insights to better their position in their businesses. The competitive landscape section includes the competitor ecosystem, new product development, agreement, and acquisitions.

visit: neurology.pencis.com

#AIDiagnosis#NeurologyMarket#FuturisticTechnology#BioMind#Arterys#BrainScientific#Methinks#NeuroAI#MedicalAI#Neuroinformatics#Neuroimaging#Neurotech#DigitalHealth#HealthTech#MedicalInnovation#PrecisionMedicine#NeurologicalDisorders#Neurodiagnostics#Neuromonitoring#BrainHealth

Pediatric Neurology Devices Market to witness growth opportunities worth USD 3.26 Bn by 2029 at a CAGR of 6.3 percent

The global Pediatric Neurology Devices Market is projected to reach from USD 2.12 Bn in 2022 to USD 3.26 Bn at a CAGR of 6.3 percent during the forecast period 2029.

Pediatric Neurology Devices Market Report Scope and Research Methodology:

Pediatric neurology is a branch of science that focuses on neurological disorders in children, such as frequent headaches and insomnia. The prevalence of neurological disorders in children is mounting rapidly, and the market is expected to grow significantly due to increasing demand for quality devices in healthcare and flourishing healthcare technology.

The report provides a detailed list of factors that will drive and restrain the growth of the pediatric neurology devices market. The report covers the segments in the pediatric neurology devices market such as product, services, neurological subspecialties, and application.

Pediatric Neurology Devices Market Dynamics:

The report also covers key developments in the pediatric neurology devices market as organic and inorganic growth strategies, including Abbott's development of low dose neurostimulation for chronic pain and the Infinity Parkinson's by delivering deep brain stimulation (DBS) system, originally developed by St. Jude Medical that became part of Abbott.

The objective of the report is to present a comprehensive analysis of the global Pediatric Neurology Devices Market, including all the stakeholders of the industry. The report also helps in understanding Global Pediatric Neurology Devices Market dynamics, structure by analyzing the market segments, and project the Global Pediatric Neurology Devices Market size.

Pediatric Neurology Devices Market Regional Insights:

North America dominates the pediatric neurology devices market share during the forecast period due to the rising incidence of diseases such as depression, epilepsy, and migraine, high healthcare spending, and cumulative government support for research & development.

Pediatric Neurology Devices Market Segmentation

By Product:

• Neurosurgery Devices

• Neurostimulator

• Cerebrospinal Fluid (CSF) Management Devices

By Service:

• Electroencephalogram

• Intrathecal Baclofen Therapy

• Neurological Evaluations

• Vagal Nerve Stimulation

By Application;

• Hospitals

• Healthcare Centers

• Neurological Research Centers

By Neurological Subspecialties:

• Neuro-Oncology

• Neuromuscular

• Neonatal Neurology

• Neuroimmunology

• Stroke

• Others

Pediatric Neurology Devices Market Key Competitors include:


• Abbot
• Elana
• Inova Healthcare System
• Medtronic
• The Nemours Foundation
• Stryker
• Boston Scientific
• B.Braun Melsungen
• Integra LifeSciences
• St. Jude Medical
• Ethicon Inc.
• Zimmer Biomet Holdings, Inc.
• Baxter International Inc.
• Co-Diagnostics, Inc.
• Russell Medical
• Geisinger Health
• Beaumont Health
• Catholic Health Initiatives

About Maximize Market Research:

Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.

visit: neurology.pencis.com

#PediatricNeurology#ChildNeurology#PediatricNeurologist#ChildNeurologist#NeurodevelopmentalDisorders#NeurologicalConditions#PediatricEpilepsy#PediatricHeadache#NeuromuscularDisorders#PediatricNeuroRehab#PediatricNeurosurgery#Neurogenetics#Neuroimaging#Neuroscience#PediatricBrainTumors#Neuropsychology#PediatricNeurodevelopment#PediatricStroke

NIH study identifies features of Long COVID neurological symptoms

Twelve people with persistent neurological symptoms after SARS-CoV-2 infection were intensely studied at the National Institutes of Health (NIH) and were found to have differences in their immune cell profiles and autonomic dysfunction. These data inform future studies to help explain persistent neurological symptoms in Long COVID. The findings, published in Neurology: Neuroimmunology & Neuroinflammation(link is external), may lead to better diagnoses and new treatments.

People with post-acute sequelae of COVID-19 (PASC), which includes Long COVID, have a wide range of symptoms, including fatigue, shortness of breath, fever, headaches, sleep disturbances, and “brain fog,” or cognitive impairment. Such symptoms can last for months or longer after an initial SARS-CoV-2 infection. Fatigue and “brain fog” are among the most common and debilitating symptoms, and likely stem from nervous system dysfunction.

Researchers used an approach called deep phenotyping to closely examine the clinical and biological features of Long COVID in 12 people who had long-lasting, disabling neurological symptoms after COVID-19. Most participants had mild symptoms during their acute infection. At the NIH Clinical Center, participants underwent comprehensive testing, which included a clinical exam, questionnaires, advanced brain imaging, blood and cerebrospinal fluid tests, and autonomic function tests.

The results showed that people with Long COVID had lower levels of CD4+ and CD8+ T cells—immune cells involved in coordinating the immune system’s response to viruses—compared to healthy controls. Researchers also found increases in the numbers of B cells and other types of immune cells, suggesting that immune dysregulation may play a role in mediating Long COVID.

Consistent with recent studies, people with Long COVID also had problems with their autonomic nervous system, which controls unconscious functions of the body such as breathing, heart rate, and blood pressure. Autonomic testing showed abnormalities in control of vascular tone, heart rate, and blood pressure with a change in posture. More research is needed to determine if these changes are related to fatigue, cognitive difficulties, and other lingering symptoms.

Taken together, the findings add to growing evidence that widespread immunological and autonomic nervous system changes may contribute to Long COVID. The results may help researchers better characterize the condition and explore possible therapeutic strategies, such as immunotherapy.

The study was supported by the Intramural Research Program at the National Institute of Neurological Disorders and Stroke (NINDS) and is part of an observational study taking place at the NIH Clinical Center designed to characterize changes in the brain and nervous system after COVID-19 (NCT04564287).

#LongCOVIDNeurology#LongCOVIDBrain#COVIDBrainFog#COVIDNeurologicalSymptoms#LongCOVIDCognitiveImpairment#COVIDNeurologyStudy#COVIDNeuroRecovery#LongCOVIDNeuroscience#COVIDNeurologicalResearch#LongCOVIDNeurologicalImpact

visit: neurology.pencis.com

Beyond the barrier: ultrasound allows AAV vectors into the brain

Researchers have successfully utilized low-intensity ultrasound to temporarily open the blood-brain barrier and deliver gene therapy directly to the brain as part of efforts to find a cure for Parkinson’s disease.

Parkinson’s disease is a neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the substantia nigra of the brain, resulting in uncontrollable movement and difficulty with coordination and balance. Current therapeutic approaches for Parkinson’s disease are aimed at alleviating symptoms rather than curing the disease.

Curative approaches for Parkinson’s disease, such as gene therapy and immunotherapy, have been limited by the difficulty in overcoming the highly selective blood-brain barrier. While invasive methods such as intracerebroventricular injections are available, these methods are associated with increased risk to patients, prompting a team of researchers led by José Obeso from CEU San Pablo University (Madrid, Spain) to seek alternative non-invasive methods.

As part of efforts to find an approach that can either stop or slow down the progression of the disease, researchers have turned to low-intensity focused ultrasound (LIFU), a non-invasive technique that has recently been shown to transiently open the blood-brain barrier. The recent study published in Science Advances describes how the team successfully employed LIFU to open the blood-brain barrier for 24-hours in six adult macaque monkeys. Following the opening of the blood-brain barrier, the team systemically administered AAV9 vectors encoding green fluorescent protein, which successfully reached the basal ganglia of the brain.

Four weeks after the delivery of the AAV9 vectors, postmortem histological analysis showed that the vector had been delivered to the targeted region in five of the macaque monkeys. Vector-induced expression of green fluorescent protein was observed in three of the five monkeys that did not have AAV9-neutralizing antibodies, which is an absence observed in half of the human population.

“Our ultimate goal is to treat neurological diseases, such as Parkinson’s, early and non-invasively,” says José Obeso, lead author of the study.

Additionally, the team reported findings from a proof-of-concept Phase 1 clinical trial conducted with three Parkinson’s patients to assess the safety and feasibility of utilizing LIFU to open the blood-brain barrier. The study described how the patients underwent 18F-choline PET imaging following the opening of the barrier with LIFU. 18F-choline is a radioactive molecule that cannot penetrate the blood-brain barrier. Blood-brain barrier openings were successfully demonstrated in the patients with the uptake of 18F-choline observed in targeted brain regions.

It is hoped that the findings from this study might offer a non-invasive approach for viral vector delivery of gene therapy for neurodegenerative disorders.

visit: neurology.pencis.com

#GeneTherapy

#ParkinsonsDisease

#Neurology

#GeneEditing

#ParkinsonsTreatment

#GeneticMedicine

#NeurodegenerativeDisorders

#ResearchAdvancements

#GeneModification

#PrecisionMedicine

#TherapeuticInterventions

#Neuroscience

#ParkinsonsResearch

#GeneticEngineering

#innovativetreatments

Deep Brain Stimulation to Treat Parkinson's Disease and Movement Disorders

 

What Is Deep Brain Stimulation?

DBS involves brain surgery to place one or more electrodes in the brain. An extension connects the leads to a battery-operated device called a neurostimulator. The neurostimulator is like a heart pacemaker, but for the brain. It is implanted in the patient's upper chest.

Once the neurologist programs the neurostimulator, it delivers small amounts of stimulation to the brain to help control abnormal brain activity. The amount of stimulation can be controlled and adjusted to manage the symptoms of Parkinson's disease, essential tremor and dystonia that do not improve with medications. Some symptoms may not improve with DBS.

DBS is an effective treatment for many patients, but it only treats the symptoms of the disease, not the disease itself. It is not a cure and does not stop the disease progression. DBS can improve such symptoms as:

• Tremor (shaking)
• Slowed movements (bradykinesia)
• Stiffness (rigidity)

How DBS Works

DBS involves implanting a thin wire, or lead, containing one or more electrodes, in the brain. The lead extends through a small opening in the skull and connects to a neurostimulator — a device that is similar to a heart pacemaker, only for the brain. The surgeon then implants the battery-operated neurostimulator under the skin in your upper chest.

After programming, the neurostimulator delivers controlled and adjustable levels of electrical signals to the brain to soothe symptoms of Parkinson’s disease, tremor and dystonia that fail to improve with medications.

Candidates for Deep Brain Stimulation

The Parkinson’s and Movement Disorders team meets weekly to review patient cases, including patients who may be candidates for the deep brain stimulation procedure. Patient selection is based on a thorough analysis of their medical situation and needs, as well as the best evidence available in medical 

literature and our extensive experience in performing DBS procedures.

Patients who have symptoms for at least 3 – 4 years.
Patients with Parkinson's disease, essential tremor and dystonia who experience movement-related symptoms that cannot be controlled by medications or experience side effects from those medications
Patients who show no significant problems with thinking and memory

New uses for DBS are being investigated, including symptom control for patients with epilepsy, Tourette’s syndrome, depression and chronic pain syndromes.

DBS has been successful in treating patients as young as 13 years old. In general, surgery is performed on patients under 75 years old, but this is not a firm guideline. Each patient must be assessed individually in regard to his or her stamina and overall health.

Thanks to significant innovation in DBS therapy, we offer three FDA-approved DBS devices. You and your movement disorder neurologist will thoroughly discuss the differences between the three options and determine which one meets your needs.

When to Consider DBS

There is a window of opportunity when DBS is an effective treatment, typically in the eight to 12-year range. If you wait beyond the window, symptoms may be too severe to respond.

For essential tremor and dystonia, DBS should be considered after symptoms have failed to improve with one or more medications and the tremor interferes with daily activities.
For Parkinson's disease, DBS should be considered if you've had symptoms for at least four years and your symptoms still respond to carbidopa-levodopa, but the medication causes significant fluctuations or side effects (wearing off, dyskinesias, freezing, dystonia).

If you qualify for DBS, you make a commitment to the process since the workup for DBS and the procedure requires several visits to the clinic and hospital. It is important to determine on medical and personal levels if DBS is right for you.

The screening and evaluation process includes multiple steps.

Consultation where we take a complete medical history and perform a neurological exam 

Videotaped off-on testing where your motor symptoms are rated after you are off medication for 12 hours, then medication is taken and you are monitored while you are on medication

Neuropsychological testing that assesses thinking skills, motor, behavioral, language and executive function (Make sure you bring any glasses or hearing aids, as well as a friend or family member.)
DBS Case Conference with the Movement Disorders team to determine if you are a good candidate.

If you are a good candidate, you will be referred to a neurosurgeon and team to develop a procedure plan.

visit : neurology.pencis.com

#DBSEffectiveness #DeepBrainStimulation #NeurologicalTreatment #NeuroscienceResearch #BrainDisorders #ParkinsonsTreatment #MovementDisorders #NeurologicalTherapy #DBSTherapy #NeurologicalAdvancements #NeurologicalHealth #NeurologicalScience #NeurologicalRehabilitation #NeurologicalDisorders #NeurologicalSurgery #NeurologicalInterventions #NeurologicalConditions #DBSResearch #BrainStimulation #NeurologicalProgress #NeurologyAdvances #NeurologicalRecovery #NeurologicalWellness #NeurologicalOutcomes #NeurologicalBreakthroughs

Brain Tumor: Symptoms

People with a brain tumor may experience the following symptoms or signs. A symptom is something that only the person experiencing it can identify and describe, such as fatigue, nausea, or pain. A sign is something that other people can identify and measure, such as a fever, rash, or an elevated pulse. Together, signs and symptoms can help describe a medical problem. Sometimes, people with a brain tumor do not have any of the signs and symptoms described below. Or, the cause of a symptom or sign may be a medical condition that is not a brain tumor.

Symptoms of a brain tumor can be general or specific. A general symptom is caused by the pressure of the tumor on the brain or spinal cord. Specific symptoms are caused when a specific part of the brain is not working well because of the tumor. For many people with a brain tumor, they were diagnosed when they went to the doctor after experiencing a problem, such as a headache or other changes.

General symptoms include:

• Headaches, which may be severe and worsen with activity or in the early morning

• Seizures. People may experience different types of seizures. Certain drugs can help prevent or control them. Motor seizures, also called convulsions, are sudden involuntary movements of a person’s muscles.

Symptoms that may be specific to the location of the tumor include:

• Pressure or headache near the tumor.
• Loss of balance and difficulty with fine motor skills is linked with a tumor in the cerebellum.
• Changes in judgment, including loss of initiative, sluggishness, and muscle weakness or paralysis is associated with a tumor in the frontal lobe of the cerebrum.
• Partial or complete loss of vision is caused by a tumor in the occipital lobe or temporal lobe of the cerebrum.
• Changes in speech, hearing, memory, or emotional state, such as aggressiveness and problems understanding or retrieving words can develop from a tumor in the frontal and temporal lobe of the cerebrum.
• Altered perception of touch or pressure, arm or leg weakness on 1 side of the body, or confusion with left and right sides of the body are linked to a tumor in the frontal or parietal lobe of the cerebrum.
• Inability to look upward can be caused by a pineal gland tumor.
• Lactation, which is the secretion of breast milk, and altered menstrual periods, as well as growth in hands and feet during adulthood, are linked with a pituitary tumor.
• Difficulty swallowing, facial weakness or numbness, or double vision is a symptom of a tumor in the brain stem.
• Vision changes, including loss of part of the vision or double vision can be from a tumor in the temporal lobe, occipital lobe, or brain stem.

If you are concerned about any changes you experience, please talk with your doctor. Your doctor will ask how long and how often you’ve been experiencing the symptom(s), in addition to other questions. This is to help figure out the cause of the problem, called a diagnosis.

If a brain tumor is diagnosed, relieving symptoms remains an important part of your care and treatment. This may be called "palliative care" or "supportive care." It is often started soon after diagnosis and continued throughout treatment. Be sure to talk with your health care team about the symptoms you experience, including any new symptoms or a change in symptoms.

#BrainTumorSymptoms #BrainTumorAwareness #KnowTheRedFlags #BrainTumorWarningSigns #BrainHealthMatters #StayInformed #HealthEducation #EarlyDetectionSavesLives

visit: neurology-conferences.pencis.com